Gilead raises 2020 profit forecast on remdesivir strength
(Reuters) - Gilead Sciences Inc raised its full-year profit forecast on Monday, as a recent resurgence in COVID-19 cases boosted demand for its COVID-19 treatment, remdesivir.
